Phase 3 trial in 577 virologically suppressed adults with HIV-1: switching to bictegravir-lenacapavir was non-inferior to continuing bictegravir-emtricitabine-tenofovir alafenamide for HIV-1 RNA ≥50 copies/mL at week 48 (1.3% v 1.0%; difference 0.3%).
RCTn = 577
Meissner et al. Safety and efficacy of switching to bictegravir-lenacapavir versus continuing bictegravir-emtricitabine-tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial